Actively Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-03
40
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma
CONDITIONS
Official Title
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years (inclusive)
- Signed informed consent form
- Measurable multiple myeloma disease by serum or urine M-protein or abnormal free light chain ratio
- Received only one standard anti-myeloma therapy line including induction, transplantation/consolidation, and maintenance
- Meet at least one dynamic high-risk criterion: early relapse within 18 months of first therapy or within 12 months post-transplant, primary refractory disease after induction, or relapse with new genetic abnormalities
- Confirmed BCMA antigen expression on myeloma cells by flow cytometry or bone marrow immunohistochemistry
You will not qualify if you...
- Primary plasma cell leukemia
- Concurrent amyloidosis
- Central nervous system involvement
- Previous treatment with BCMA-targeted therapy or CAR-T cell therapy
- Disease progression or relapse within 3 months of autologous hematopoietic stem cell transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China
Actively Recruiting
Research Team
G
Gang An, PhD&MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here